相关实验视频
Updated: May 23, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.5K
对于协同性血栓溶解治疗的素响应和序列定向纳米平台
Huijuan Zhang1,2, Chaoqun Wang1, Yaning Wang1
1School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
ACS applied materials & interfaces
|March 7, 2025
概括
一个新的纳米平台,MMSN-UK/TI@pep-Fuco,提供有针对性的血栓溶解,降低出血风险. 这种先进的系统有效地溶解血栓,并防止在动脉血栓治疗中重新栓塞.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 传统的血栓溶解疗法面临挑战,包括低特异性,出血并发症和二次再栓塞.
- 开发有针对性的药物输送系统对于提高治疗疗效和安全至关重要.
研究的目的:
- 开发一种对血栓激素有反应的,顺序向的纳米平台 (MMSN-UK/TI@pep-Fuco) 进行高效的血栓溶解.
- 整合一个攻击-防御-保护策略,以改善动脉血栓症的治疗结果.
主要方法:
- 通过 (pep) 连接,通过fucoidan (Fuco) 修饰的多层中性孔性纳米颗粒 (MMSN) 的合成.
- 在MMSN@pep-Fuco中顺序加载尿素激酶 (英国) 和铁洛非班 (TI),以创建纳米药物递送系统 (NDDS).
- 在体外和体内对NDDS稳定性,向性,药物释放动力学和血栓缓解疗效的评估.
主要成果:
- MMSN-UK/TI@pep-Fuco在血液循环中表现出稳定性,降低出血风险.
- 福科通过P-选择因子相互作用促进了对血栓的活性向.
- 血素触发的FUCO分泌使得英国快速释放血栓溶解,随后持续释放TI以防止再栓塞.
- 达到4.87%的低血栓阻塞率,出血量最小.
结论:
- 开发的纳米平台为动脉血栓治疗提供了有效的策略.
- 综合攻击-防御-保护方法增强了血栓溶解并最大限度地减少了不良影响.
- 这种纳米平台对未来在血管疾病中的治疗应用具有前景.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
588
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
588
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Clot Retraction and Fibrinolysis
3.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.2K
Extrinsic and Intrinsic Pathways of Hemostasis
4.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.6K

